Esmodac IT 40mg/150mg Capsule

Introduction

Esmodac IT is a prescription medication that contains two active ingredients: Esomeprazole and Itopride. Esomeprazole is a proton pump inhibitor (PPI) that reduces the production of stomach acid, while Itopride is a prokinetic agent that enhances gastrointestinal motility. Together, these two ingredients work synergistically to provide relief from certain gastrointestinal conditions.

Uses

Esmodac IT is primarily prescribed to treat the following conditions:

• Gastroesophageal Reflux Disease (GERD): It helps reduce the symptoms of GERD, such as heartburn, by reducing the production of stomach acid and promoting healing of the esophagus.
• Non-Ulcer Dyspepsia: It relieves symptoms of non-ulcer dyspepsia, including bloating, stomach discomfort, and early satiety.
• Functional Dyspepsia: Itopride helps improve symptoms of functional dyspepsia, such as postprandial fullness and epigastric pain.
• Gastroparesis: Itopride enhances gastric emptying and improves symptoms of gastroparesis, a condition characterized by delayed stomach emptying.

Dosage and Administration

• The recommended dosage of Esmodac IT is one capsule to be taken twice daily, preferably before meals.
• Swallow the capsule whole with a glass of water. Do not crush or chew the capsule.
• follow the prescribed dosage and not exceed it without consulting your healthcare provider.
• If you forget to take a dose, take it as soon as you remember. However, if it is almost time for the next dose, skip the missed dose and continue with your regular dosing schedule.

Mechanism of Action

Esomeprazole, one of the active ingredients in Esmodac IT, works by inhibiting the enzyme responsible for acid production in the stomach. By reducing stomach acid secretion, it helps alleviate symptoms associated with conditions like GERD and non-ulcer dyspepsia.

Itopride, the other active ingredient, acts as a prokinetic agent. It enhances gastrointestinal motility, which helps improve the movement of food through the digestive system. This can be beneficial for individuals experiencing symptoms of functional dyspepsia and gastroparesis.

Side Effects

Common side effects that may occur include:

• Headache
• Nausea
• Diarrhea
• Abdominal pain
• Flatulence

These side effects are usually mild and temporary. However, if any of these side effects persist or worsen. Inform your healthcare provider.

In rare cases, Esmodac IT may cause more serious side effects. If you experience any of the following, seek immediate medical attention:

• Severe allergic reactions (e.g., rash, itching, swelling, severe dizziness)
• Difficulty breathing or swallowing
• Chest pain or irregular heartbeat
• Severe abdominal pain or persistent vomiting

Drug Interactions

Esmodac IT may interact with certain medications. Inform your healthcare provider about all the medications you are currently taking, including prescription, over-the-counter, and herbal products. Some common drug interactions include:

• Clopidogrel: Esomeprazole may reduce the effectiveness of clopidogrel, a medication used to prevent blood clots.
• Warfarin: Esomeprazole may increase the risk of bleeding when taken with warfarin, an anticoagulant.
• Digoxin: Esomeprazole may increase the levels of digoxin in the blood, potentially leading to toxicity.

These are just a few examples, and there may be other potential drug interactions. Your healthcare provider will determine the appropriate treatment plan and monitor for any potential interactions.

Precautions

Before taking Esmodac IT, consider the following precautions:

• Inform your healthcare provider about any allergies or sensitivities you may have.
• If you have a history of liver disease or are taking other medications that may affect liver function, discuss this with your healthcare provider.
• Inform your healthcare provider if you are pregnant, planning to become pregnant, or breastfeeding.
• Esmodac IT may interact with certain other medications and substances, including alcohol. Avoid or limit alcohol consumption while taking this medication.
• If you experience any new or unusual symptoms while taking Esmodac IT, contact your healthcare provider for further evaluation.

Storage

Esmodac IT should be stored at room temperature, away from moisture and heat. Keep it in its original packaging, and out of reach of children and pets. Do not use the medication if it has expired or if the packaging is damaged.

Patient Tips

Here are some additional tips for patients using Esmodac IT:

• Take the medication exactly as prescribed by your healthcare provider.
• If you have difficulty swallowing the capsule, speak to your healthcare provider about alternative forms of the medication.
• Maintain a healthy lifestyle by following a balanced diet and engaging in regular physical activity.
• If you experience any new or worsening symptoms while taking Esmodac IT, consult your healthcare provider.
• Attend all scheduled follow-up appointments with your healthcare provider to monitor your response to the medication and discuss any concerns or questions you may have.

Please note that this description, as well as the other content on our website is for educational purposes only. We do not provide medical advice. For specific medical advices, diagnoses and treatment options you should consult with your doctor.

References

• Esomeprazole: medicine to lower stomach acid (NHS UK) [Accessed 18 Jun. 2024] (online) Available at:
• Boots Heartburn and Acid Reflux Control 20mg Gastro-Resistant Capsules (Health Professionals SmPC) Available at:
• Esomeprazole (Drugs.com) [Accessed 3 Jun. 2024] (online) Available at:
• esomeprazole mag-glycerin kit, capsule delayed release and spray (kit, dr spray) (RX) [Accessed 27 Jun. 2024] (online) Available at:
• Omeprazole (MedlinePlus) [Accessed 8 Jun. 2024] (online) Available at:
• Qi Q, Wang R, Liu L, Zhao F, Wang S. Comparative effectiveness and tolerability of esomeprazole and omeprazole in gastro-esophageal reflux disease: A systematic review and meta-analysis. Int J Clin Pharmacol Ther. 2015 Oct;53(10):803-10. doi: 10.5414/CP202396. [Accessed 15 Jun. 2024] Available at: